CBL-514, placebo + CBL-514, placebo + CBL-514
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Subcutaneous Fat
Conditions
Subcutaneous Fat
Trial Timeline
Nov 27, 2018 → Aug 20, 2019
NCT ID
NCT04699669About CBL-514, placebo + CBL-514, placebo + CBL-514
CBL-514, placebo + CBL-514, placebo + CBL-514 is a phase 1 stage product being developed by Caliway Biopharmaceuticals for Subcutaneous Fat. The current trial status is completed. This product is registered under clinical trial identifier NCT04699669. Target conditions include Subcutaneous Fat.
What happened to similar drugs?
0 of 3 similar drugs in Subcutaneous Fat were approved
Approved (0) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04699669 | Phase 1 | Completed |
Competing Products
9 competing products in Subcutaneous Fat
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| TR-701 FA + Linezolid | Merck | Phase 3 | 40 |
| TR-701 FA + Linezolid | Merck | Phase 3 | 40 |
| CBL-514 | Caliway Biopharmaceuticals | Phase 2 | 35 |
| CBL-514 Injection | Caliway Biopharmaceuticals | Phase 2 | 35 |
| CBL-514 Injection | Caliway Biopharmaceuticals | Phase 2 | 35 |
| CBL-514 Injection | Caliway Biopharmaceuticals | Phase 3 | 47 |
| CBL-514 | Caliway Biopharmaceuticals | Phase 2 | 35 |
| CBL-514 | Caliway Biopharmaceuticals | Phase 2 | 35 |
| CBL-514 injection + CBL-A1 Injection + CBL-A2 Injection + 0.9% Sodium Chloride | Caliway Biopharmaceuticals | Phase 2 | 35 |